Medical Device and Healthcare Industry Trends — 2026-09-08
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Samsung Medison has launched its AI-powered obstetrics and gynecology ultrasound system, the HERA Z10, achieving a 52% reduction in scan times. Meanwhile, the global medtech sector is seeing accelerated regulatory relief, highlighted by the FDA launching the TEMPO pilot program to allow pre-market clinical use of generative AI medical devices. In South Korea, regulatory frameworks continue to be refined, including updates to the Ministry of Food and Drug Safety's digital medical product classifications.
Medical Device and Healthcare Industry Trends — 2026-09-08
Top 5 Headlines Today
- Samsung Medison launches AI-powered obstetrics and gynecology ultrasound 'HERA Z10', cutting scan times by up to 52%
- FDA selects 4 companies for the 'TEMPO' pilot program, allowing pre-market use of generative AI medical devices
- FDA releases regulatory relief guidelines for wearable and AI-powered digital health products
- MFDS implements partial amendments to regulations on medical device items and item-specific grades (Notice No. 2026-18)
- Global digital healthcare venture investment slump persists, with the digital therapeutics (DTx) sector facing particularly sluggish conditions
Key Company Trends (At least 4 items)
Samsung Medison
- What happened: Launched the 'HERA Z10', a premium AI-powered obstetrics and gynecology ultrasound system
- Key figures: Reduced second-trimester scan times by up to 52%
- Implications: Samsung Medison has introduced a new product that maximizes diagnostic efficiency by integrating AI technology. This is expected to revolutionize workflows in obstetrics and gynecology clinics and help reduce patient waiting times.
MFDS · Policy · Regulation (At least 3 items)
MFDS Implements Partial Amendment to Medical Device Grading Regulations
- Details: Implementation of partial amendments to the "Regulations on Medical Device Items and Item-Specific Grades" (Notice No. 2026-18)
- Target: General medical device manufacturers and importers
- Effective Date: March 9, 2026 (included in recent notice lists)
- Industry Impact: Classification criteria based on medical device risk levels have changed, which may alter approval and notification procedures or quality management requirements for certain items. In accordance with this notice revision, regulations on the approval, notification, and review of in vitro diagnostic medical devices were also revised.
MFDS Abolishes Grace Period for Sales Suspension Upon Violations of Periodic Medical Device GMP Audits
- Details: The 'sales suspension grace period' previously applied for violations of periodic medical device GMP audits has been abolished. Products that fail to comply with standards before their GMP validity period expires cannot be imported or sold.
- Target: In vitro diagnostic medical device manufacturers and importers
- Effective Date: In effect as of the March 26, 2026 report
- Industry Impact: Obligations to comply with Good Manufacturing Practices (GMP) have been strengthened, resulting in immediate sales suspension measures for periodic audit violations or upon expiration of validity periods. This further increases the importance of establishing and maintaining quality management systems for manufacturers.
MFDS Implements 'Immediate Market Entry' System for Innovative Medical Devices
- Details: Established the 'Immediate Market Entry Medical Technology' system to enhance market access for innovative medical devices, officially implemented following a pilot program.
- Target: Innovative medical devices applying advanced technologies such as AI and big data
- Effective Date: January 26, 2026 (as of report date)
- Industry Impact: A pathway has opened for products designated as innovative medical devices to enter the market under certain conditions even before receiving approval. This is expected to accelerate the early commercialization of new technology medical devices and improve patient access.
Digital Health · AI Healthcare (At least 3 items)
- Samsung Medison HERA Z10: Applied technology utilizing AI algorithms to reduce obstetrics and gynecology ultrasound scan times by 52%
- FDA TEMPO Pilot Program: Four companies, including Cadence and Limbic, had their generative AI medical devices selected for the FDA's TEMPO pilot program, allowing real-world patient use prior to marketing authorization
- FDA Eases Regulations for Low-Risk AI Software: The FDA released new guidelines easing oversight on low-risk AI health software and wearable devices while maintaining regulations for high-risk medical devices
Global Medtech Context
- FDA Allows Pre-Market Use of Generative AI Medical Devices (TEMPO) — Implications for Korean Industry: The FDA's TEMPO pilot program could provide new opportunities for Korean companies to validate AI medical devices and secure data in the U.S. market.
- FDA Eases Regulations on Wearables and AI — Implications for Korean Industry: A foundation has been established for Korean-made wearable devices, such as the Samsung Galaxy Ring, to lower FDA regulatory barriers and enter the U.S. market more rapidly.
- Criticism of Insufficient Clinical Validation for AI Medical Devices — Implications for Korean Industry: A report noting that only 3 out of 1,357 FDA-approved AI medical devices have been validated for actual patient outcomes highlights the importance of securing clinical efficacy data in future AI medical device development.
Investment · M&A · IPO Trends
- Global Digital Healthcare VC Slump: Global venture investment in digital healthcare sectors, including digital therapeutics (DTx), has dropped sharply, showing an even tighter contraction in Q2 compared to Q1.
- Domestic Digital Health Startup Investment Attraction Case: GIBITA secured a Series A investment worth KRW 4.5 billion and plans to focus on developing services targeting pre-diabetic patients.
Insight of the Day
As the MFDS's immediate market entry system for innovative medical devices aligns with the FDA's easing of AI medical device regulations (the TEMPO pilot program and reduced oversight for low-risk products), the global market entry environment for Korean AI and digital healthcare companies is improving. However, amidst the global venture investment slump, clear clinical efficacy data and business model profitability—alongside technological prowess—are emerging as core criteria for securing investments.
Checkpoints This Week
- Check whether your product lines require classification changes according to the MFDS medical device item grading amendment notice (Notice No. 2026-18)
- Monitor whether companies selected for the FDA TEMPO pilot program release initial clinical data and safety reports
- Check for upcoming global digital healthcare investment trend reports and domestic startup follow-up investment round announcements
Reader Action Items
- Review MFDS Notice No. 2026-18 to examine whether your medical devices' item-specific grades have changed.
- Analyze the impact of the FDA's new AI/wearable regulatory relief guidelines on your company's U.S. market entry strategy.
- For digital therapeutics (DTx) businesses, focus on cash flow management and profitability model validation amid the global investment slump.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
